"But if I were to take a stab, I would say Roche!"
Certainly a leading candidate.
Then there's GSK because of the Axel Hoos link.
Merck know Paul Hopper well, having done the Viralytics deal.
But there are plenty of others that will be interested. A bidding war would be fun!
I would pick Merck as the likely one, being as Keytruda has heaps of safety concerns.
cheers
Media Thread, page-1001
-
- There are more pages in this discussion • 14,858 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.001(2.04%) |
Mkt cap ! $357.0M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $279.2K | 5.733M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 94 | 12992150 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 1795056 | 6 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |